Welcome to our dedicated page for JANUS LIVING news (Ticker: JAN), a resource for investors and traders seeking the latest updates and insights on JANUS LIVING stock.
Janus Living, Inc. reports developments as a pure-play senior housing real estate investment trust focused on senior housing communities across the United States. Company news centers on quarterly operating results, same-store revenue, occupancy and RevPOR trends, dividend declarations, liquidity actions, acquisition and investment activity, and the use of proceeds from its completed initial public offering.
Recurring updates also address Janus Living’s Class A-1 common stock trading on the New York Stock Exchange, its external management relationship with Healthpeak Properties, and capital resources such as unsecured revolving credit and term loan facilities used for general corporate purposes and portfolio growth.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
JanOne (NASDAQ: JAN) announced a successful pre-IND meeting with the FDA on April 18, 2023, regarding Jan123, a low dose naltrexone aimed at treating complex regional pain syndrome (CRPS). This rare disease causes severe pain and has no current cure. The FDA's feedback gives JanOne a pathway for submitting a New Drug Application under the 505(b)(2) designation. Key discussion points included preclinical toxicology and clinical implementation, which are crucial for progressing Jan123 towards formal approval. Both JanOne's Chief Medical Officer and CEO expressed optimism about the therapeutic potential of Jan123 and its role in addressing the opioid crisis. The company emphasizes its commitment to innovative pain management solutions.
JanOne (Nasdaq: JAN), represented by Dr. Amol Soin, will present at the Appalachian Region Spine and Pain Meeting on April 15, 2023, discussing innovation in pain medicine and the company’s drug development programs. JanOne focuses on non-opioid treatments for pain management, introducing two late-stage drug candidates: JAN 101, aimed at treating peripheral artery disease and diabetic neuropathy, and JAN 123, a low-dose naltrexone for Complex Regional Pain Syndrome, which received orphan drug status from the FDA. Dr. Soin aims to highlight the need for effective pain management solutions amid the opioid crisis, which underscores JanOne's commitment to developing non-addictive medication options. The meeting will serve as a platform to engage physicians seeking alternatives to opioids.
JanOne, a biopharmaceutical company on Nasdaq (JAN), announced the appointment of John N. Bonfiglio, PhD, as the interim president of its subsidiary, JanOne Biotech. His extensive background in leading successful biotech firms includes raising over $50 million for clinical trials at Immune Response Corporation. Bonfiglio aims to enhance JanOne's pain management solutions for conditions like diabetic neuropathy and Peripheral Artery Disease (PAD). CEO Tony Isaac expressed optimism for Bonfiglio's contributions to the company. The release also includes forward-looking statements which highlight potential developments while cautioning about related risks.